Statements (13)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:monoclonal_antibody
|
| gptkbp:administeredBy |
intravenous infusion
|
| gptkbp:affiliatedWith |
immunotherapy
|
| gptkbp:alternativeName |
ublituximab
|
| gptkbp:clinicalTrialPhase |
Phase 3
|
| gptkbp:developedBy |
TheraMAB LLC
|
| https://www.w3.org/2000/01/rdf-schema#label |
TG1101
|
| gptkbp:mechanismOfAction |
B-cell depletion
|
| gptkbp:target |
gptkb:CD20
|
| gptkbp:usedFor |
multiple sclerosis
chronic lymphocytic leukemia |
| gptkbp:bfsParent |
gptkb:Wymondham,_Norfolk,_England
|
| gptkbp:bfsLayer |
8
|